OraSure Technologies (NASDAQ:OSUR) Rating Lowered to Sell at Wall Street Zen

OraSure Technologies (NASDAQ:OSUR) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday.

Separately, Weiss Ratings raised OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, OraSure Technologies presently has an average rating of “Reduce” and a consensus price target of $3.00.

OraSure Technologies Price Performance

OraSure Technologies stock opened at $4.16 on Friday. OraSure Technologies has a 1-year low of $2.08 and a 1-year high of $4.58. The company has a market cap of $286.42 million, a PE ratio of -4.00 and a beta of 1.00. The stock’s 50 day moving average price is $4.17 and its 200 day moving average price is $3.39.

Insider Transactions at OraSure Technologies

In related news, Director Steven Kyle Boyd purchased 25,000 shares of OraSure Technologies stock in a transaction dated Thursday, May 14th. The stock was bought at an average cost of $2.99 per share, for a total transaction of $74,750.00. Following the transaction, the director owned 113,462 shares in the company, valued at approximately $339,251.38. The trade was a 28.26% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On OraSure Technologies

A number of institutional investors and hedge funds have recently modified their holdings of OSUR. Sei Investments Co. increased its stake in OraSure Technologies by 16.4% in the 3rd quarter. Sei Investments Co. now owns 32,244 shares of the medical instruments supplier’s stock valued at $103,000 after purchasing an additional 4,536 shares in the last quarter. Russell Investments Group Ltd. boosted its position in OraSure Technologies by 13.3% during the fourth quarter. Russell Investments Group Ltd. now owns 43,636 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 5,138 shares in the last quarter. Hsbc Holdings PLC boosted its position in OraSure Technologies by 4.6% during the first quarter. Hsbc Holdings PLC now owns 141,309 shares of the medical instruments supplier’s stock worth $421,000 after purchasing an additional 6,218 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in OraSure Technologies by 102.2% in the third quarter. BNP Paribas Financial Markets now owns 15,275 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 7,720 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in OraSure Technologies by 32.7% in the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 8,133 shares during the last quarter. Institutional investors and hedge funds own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.